Smith & Nephew plc (LON:SN) Receives GBX 1,185.86 Consensus Target Price from Analysts

Shares of Smith & Nephew plc (LON:SN) have been given an average rating of “Hold” by the seven analysts that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is GBX 1,185.86.

Several research firms have issued reports on SN. UBS Group restated a “neutral” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a report on Tuesday, May 5th. Royal Bank Of Canada lowered shares of Smith & Nephew to a “sector perform” rating and set a GBX 1,350 price target for the company. in a report on Thursday, May 7th. Finally, Berenberg Bank restated a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a report on Friday, May 1st.

Smith & Nephew Stock Performance

Smith & Nephew stock opened at GBX 1,145 on Thursday. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The stock’s 50-day moving average price is GBX 1,191.01 and its 200 day moving average price is GBX 1,239.83. The company has a market cap of £12.55 billion, a price-to-earnings ratio of 41.22, a price-to-earnings-growth ratio of 0.46 and a beta of 0.67.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.